Combined BRAFV600E-positive melanocytic lesions with large epithelioid cells lacking BAP1 expression and conventional nevomelanocytes

American Journal of Surgical Pathology

Volumn 37, Issue 2, 2013, Pages 193-199

  Busam, Klaus J ^a   Sung, Joanne ^b   Wiesner, Thomas ^a   Von Deimling, Andreas ^c,d   Jungbluth, Achim ^e  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Department of Dermatology ^*  (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

BAP1; BRAF; combined nevus; immunohistochemistry; spitz nevus

Indexed keywords

B RAF KINASE; BAP1 PROTEIN, HUMAN; BRAF PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ADOLESCENT; ADULT; ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; EPITHELIOID CELL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MELANOCYTE; METABOLISM; METHODOLOGY; MIDDLE AGED; NEVUS; PATHOLOGY; SKIN TUMOR;

ADOLESCENT; ADULT; CELL NUCLEUS; CELL PROLIFERATION; EPITHELIOID CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOCYTES; MIDDLE AGED; NEVUS, EPITHELIOID AND SPINDLE CELL; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; YOUNG ADULT;

MLCS; MLOWN;

EID: 84872867965     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e318263648c     Document Type: Article

References (26)

1. Barnhill RL, Argenyi ZB, From L, et al. Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol. 1999;30:513-520.
2. Barnhill RL. The Spitzoid lesion: rethinking Spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment. Mod Pathol. 2006;19(suppl 2):S21-S33.
3. Busam KJ, Murali R, Pulitzer M, et al. Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas. Am J Surg Pathol. 2009;33:1386-1395.
4. Cerroni L, Barnhill R, Elder D, et al. Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am J Surg Pathol. 2010;34:314-326.
5. Wiesner T, Murali R, Fried I, et al. A distinct subset of atypical spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. Am J Surg Pathol. 2012;36:818-830.
6. Wiesner T, Obenauf AC, Murali R, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet. 2011;43: 1018-1021.
7. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122:11-19.
8. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121: 397-405.
9. Andrulis M, Penzel R, Weichert W, et al. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol. 2012, April 22 [Epub ahead print].
10. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012;123:223-233.
11. Ross AL, Sanchez MI, Grichnik JM. Molecular nevogenesis. Dermatol Res Pract . 2011;2011:463184.
12. Wilson MA, Nathanson KL. Molecular testing in melanoma. Cancer J. 2012;18:117-123.
13. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19-20.
14. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62:6997-7000.
15. Broekaert SM, Roy R, Okamoto I, et al. Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res. 2010;23:763-770.
16. Viros A, Fridlyand J, Bauer J, et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 2008;5:e120.
17. Si L, Kong Y, Xu X, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer. 2012;48: 94-100.
18. Carvajal RD, Antonescu CR,Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305:2327-2334.
19. Bastian BC, LeBoit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol. 2000;157:967-972.
20. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457:599-602.
21. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363:2191-2199.
22. Abdel-Rahman MH, Pilarski R, Cebulla CM, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011;48:856-859.
23. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330: 1410-1413.
24. Njauw CN, Kim I, Piris A, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One. 2012;7:e35295.
25. Harvell JD, Meehan SA, LeBoit PE. Spitz's nevi with halo reaction: a histopathologic study of 17 cases. J Cutan Pathol. 1997;24: 611-619.
26. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43: 668-672.